8 pending office actions • 6 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Sophy Inc. | 3 |
| Arrapoi, Inc. | 1 |
| Senstasy, Inc. | 1 |
| Liveleaf Holdings, LLC | 1 |
| Gn Incorporation Co. Ltd. | 1 |
| Gn Corporation Co. Ltd. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19365437 | UNIQUE INPUT-RESPONSE RELATIONSHIPS FROM PARAMETER SETS HAVING A REDUCED SCALE AND A REDUCED NUMBER OF VARIABLES | Arrapoi, Inc. | VINCENT, DAVID ROBERT | 2123 | Non-Final OA | Oct 22, 2025 |
| 18983200 | MACHINE LEARNING FOR MODELING PREFERENCE DATA TO OPTIMIZE INTERACTIONS WITH CANDIDATE PARTNERS | Senstasy, Inc. | O'SHEA, BRENDAN S | 3626 | Non-Final OA | Dec 16, 2024 |
| 18772973 | ORALLY SAFE BINDING SYSTEMS FOR TREATING DISEASE | Liveleaf Holdings, LLC | EDWARDS, JESSICA FAYE | 1657 | Non-Final OA | Jul 15, 2024 |
| 18572416 | A COMPOSITION FOR IMPROVING, PREVENTING AND/OR TREATING MUSCULAR DYSTROPHY, MULTIPLE SCLEROSIS AND/OR RELATED DISEASES | Sophy Inc. | MCINTOSH III, TRAVISS C | 1693 | Non-Final OA | Dec 20, 2023 |
| 18569553 | BETA-GLUCAN FOR PREVENTING AND/OR TREATING FIBROSIS AND RELATED DISEASES | Sophy Inc. | MCINTOSH III, TRAVISS C | 1693 | Non-Final OA | Dec 12, 2023 |
| 18554442 | A COMPOSITION FOR IMPROVING GUT MICROBIOTA, BEHAVIOURAL PATTERN, ALPHA-SYNUCLEIN LEVELS, SLEEP PATTERN AND/OR SERUM MELATONIN | Sophy Inc. | CHO, DAVID H | 1693 | Non-Final OA | Oct 06, 2023 |
| 18027892 | CELL POPULATION PRODUCTION METHOD | Gn Incorporation Co. Ltd. | TAKENAKA, RISA | 1632 | Non-Final OA | Mar 22, 2023 |
| 17800307 | METHOD FOR CULTURING CELLS DERIVED FROM EPITHELIAL TISSUE, AND COMPOSITION CONTAINING CELLS CULTURED BY SAID CULTURE METHOD | Gn Corporation Co. Ltd. | ROGERS, ERIC JASON | 1638 | Non-Final OA | Aug 17, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial